Whereas extra giant employers are overlaying GLP-1 medicine for weight reduction, conversations with employers spotlight considerations about the price of these medicines. Many of those employers have thought-about scaling again protection of GLP-1 agonists for weight reduction, or in some circumstances, employers are including or strengthening protection necessities.
This analysis discusses findings from the 2025 KFF Employer Health Benefits Survey, with insights gained from interviews and group discussions with human assets administrators and others who handle employer well being advantages. These conversations occurred in 5 focus teams throughout the USA, overlaying over 100 firms using over 1 / 4 of one million individuals, held all through the summer time and fall of 2025.
The complete evaluation and different knowledge on well being prices can be found on the Peterson-KFF Health System Tracker, a web-based data hub devoted to monitoring and assessing the efficiency of the U.S. well being system.
